Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental cancer pill targets Hard-to-Treat tumors

NCT ID NCT06560645

Disease control Sponsor: Prelude Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested an experimental oral drug called PRT7732 in people with advanced solid tumors that have a specific genetic mutation (SMARCA4). The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PRT7732 (an oral drug that targets and degrades a protein called SMARCA2)
What this could lead to
If successful, this could point toward a new treatment option for people with certain advanced cancers that have a SMARCA4 mutation.
What could go wrong
This was a very early (Phase 1) trial with only 42 participants, and it was terminated, meaning results may be limited. The drug may not shrink tumors or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

42 people

The number who actually took part.

Started

Nov 2024

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations (including contraception requirements), and other study procedures * Histologically confirmed advanced, recurrent, or metastatic solid tumor malignancy with any mutation of SMARCA4 by local testing that has either progressed on or is ineligible for standard of care therapy * Must have measurable or non-measurable (but evaluable) disease per RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Willing to provide either archival or fresh tumor tissue sample * Adequate organ function (hematology, renal, and hepatic) Exclusion Criteria: * Participants with solid tumors with known concomitant SMARCA2 mutation or loss of protein expression * Clinically significant or uncontrolled cardiac disease, uncontrolled electrolyte disorders, uncontrolled or symptomatic central nervous system (CNS) metastases or leptomeningeal disease * History of other malignancy within 3 years except for adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, prostate adenocarcinoma with Gleason score of 3+3 or less, carcinoma in situ of the cervix, or other non-invasive or indolent malignancies, or malignancies previously treated with curative intent and not on active therapy or expected to require treatment or recurrence during the study * Receipt of any targeted therapy directed against BRM/BRG1 (SMARCA2/SMARCA4).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus esophageal adenocarcinoma esophageal squamous cell carcinoma gastric adenocarcinoma gastric squamous cell carcinoma gastroesophageal junction adenocarcinoma metastatic malignant neoplasm neoplasm Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced solid tumor Esophageal adenocarcinoma Esophageal squamous cell carcinoma Gastric adenocarcinoma Gastric squamous cell carcinoma Gastroesophageal junction adenocarcinoma Gastroesophageal junction squamous cell carcinoma Metastatic solid tumor Non-small cell lung carcinoma SMARCA4 mutation

Contacts and locations

Locations

  • Border Medical Oncology Research Unit

    Albury, New South Wales, 2640, Australia

  • Brigitte Harris Cancer Pavilion

    Detroit, Michigan, 48202, United States

  • Cancer Institute Hospital of JFCR

    Koto-ku, Tokyo, 135-8550, Japan

  • Hospital Universitario HM Sanchinarro

    Madrid, 28050, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Kindai University Hospital

    Sayama, Osaka, 589-8511, Japan

  • Linear Clinical Research Ltd

    Nedlands, Western Australia, 6009, Australia

  • Memorial Sloan Kettering Cancer Center - Main Campus

    New York, New York, 10065, United States

  • Monash Health

    Clayton, Victoria, 3168, Australia

  • National Cancer Center

    Goyang-si, Gyeonggi-do, 10408, South Korea

  • National Cancer Center Hospital

    Chuo Ku, Tokyo, 104-0045, Japan

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Scientia Clinical Research Ltd

    Randwick, New South Wales, 2031, Australia

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

  • Southern Highlands Cancer Centre

    Bowral, New South Wales, 2576, Australia

  • Start Madrid-FJD, Hospital Universitario Fundacion Jimenez Diaz-Servicio de Oncologia

    Madrid, 28040, Spain

  • Technische Universitat Dresden, Medizinlsche Fakultat Carl Gustav Carus Nationales Centrum fur Tumorerkrankungen Dresden, Early Clinical Trial Unit (NCT/UCC ECTU)

    Dresden, Saxony, 01307, Germany

  • The Univerity of Osaka Hospital

    Suita, Osaka, 565-0871, Japan

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California, 94158, United States

  • UNC Hospitals, The University of North Carolina Chapel Hill

    Chapel Hill, North Carolina, 27514, United States

  • University Clinic Cologne, Clinic for Internal Medicine

    Cologne, North Rhine-Westfalia, 50937, Germany

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106, United States

  • University of Virginia Comprehensive Cancer Center

    Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.